SA160G51UO10
SA160G51UO10
Middle East Pharmaceutical Indu
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 2.21B EUR | 2.12B EUR | 1.95B EUR | 2.22B EUR |
Enterprise Value | 2.28B EUR | 2.21B EUR | 2.01B EUR | 2.25B EUR |
Valuation Multiples | ||||
Trailing P/E | 26.14x | 19.52x | 18.65x | 28.66x |
Forward P/E | 12.4x | -- | -- | -- |
Price to Sales | 4.32x | 4.14x | 3.95x | 6.12x |
Price to Book | 4.97x | 4.75x | 4.67x | 5.34x |
EV/Revenue | 4.46x | 4.32x | 4.08x | 6.21x |
EV/EBITDA | 17.51x | 15.39x | 14.65x | 22.19x |
Price to FCF (P/FCF) | -- | 100.4x | 58.09x | 57.39x |
EV/FCF | -- | 104.95x | 60.02x | 58.15x |
FCF Yield | -1.04% | 1% | 1.72% | 1.74% |